quantic69/iStock via Getty Images
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales
Sep. 15, 2025 1:29 PM ETS&P 500 Index (SP500)AAPL, SMH, XLF, XLK, IYF, IYW, AMZN, MSFT, GGME, NVDA, KBE, XPH,...
While it may be assumed that recent college graduates aren’t ready to take on the AI-burdened job market, the ones...
This live blog is refreshed periodically throughout the day with the latest updates from the market. To find the latest...
Israeli Prime Minister Benjamin Netanyahu spoke today about Israel's international diplomatic isolation and said the country would be required,...
Gold was trading with mild weakness on Monday amid profit booking ahead of the US Federal Reserve's monetary policy meeting...
Just three months after returning to the top job, Indeed CEO Hisayuki “Deko” Idekoba says he’s regularly working 15-hour days...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
